This is a preview of subscription content, log in via an institution to check access.
References
O′Hare T, Eide CA, Deininger MW . Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242–2249.
Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–1079.
Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature reviews 2005; 5: 172–183.
Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 2007; 109: 2147–2155.
Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698.
Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006; 107: 4250–4256.
Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G et al. Germline KRAS mutations cause Noonan syndrome. Nature genetics 2006; 38: 331–336.
Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science (New York, NY) 2006; 314: 268–274.
Soddu S, Blandino G, Scardigli R, Martinelli R, Rizzo MG, Crescenzi M et al. Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes. Mol cell biol 1996; 16: 487–495.
Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374–379.
Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM . Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007; 109: 2171–2181.
Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941–1949.
Acknowledgements
This study was supported in part by NHLBI Grant HL082978-01 (MWD) and by the Leukemia and Lymphoma Society (MWD).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Agarwal, A., Eide, C., Harlow, A. et al. An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia 22, 2269–2272 (2008). https://doi.org/10.1038/leu.2008.124
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.124
- Springer Nature Limited
This article is cited by
-
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
Nature Communications (2017)
-
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy
Molecular Diagnosis & Therapy (2016)
-
Chronic Myeloid Leukemia: Advances in Understanding Disease Biology and Mechanisms of Resistance to Tyrosine Kinase Inhibitors
Current Hematologic Malignancy Reports (2015)
-
The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer
Molecular Biology Reports (2013)
-
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
International Journal of Hematology (2013)